Regulatory Developments May 2019

03a_RegNews_Alternate_770x2953.jpg

Seeking OMB approval, FDA guidances on Nonproprietary Naming of Biological Products and cancer clinical trial eligibility criteria, and more.

Related Stories

Table of Contents
Regulatory Developments
May 2019